scholarly article | Q13442814 |
P50 | author | Beatrice H. Hahn | Q55293537 |
Tanmoy Bhattacharya | Q55414889 | ||
Alan S. Perelson | Q55719625 | ||
George M. Shaw | Q78514357 | ||
Ruy M. Ribeiro | Q30504775 | ||
P2093 | author name string | Hui Li | |
Elena E Giorgi | |||
Shuyi Wang | |||
Ruian Ke | |||
Richard J O Barnard | |||
Wenge Ding | |||
P2860 | cites work | Avoiding the void: cell-to-cell spread of human viruses | Q22251022 |
Beneficial mutation selection balance and the effect of linkage on positive selection | Q24685465 | ||
Viral quasispecies evolution | Q27013917 | ||
Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication | Q27472912 | ||
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs | Q27473092 | ||
Viral and Cellular Determinants of Hepatitis C Virus RNA Replication in Cell Culture | Q27473345 | ||
Superinfection Exclusion in Cells Infected with Hepatitis C Virus | Q27478378 | ||
Analysis of Hepatitis C Virus Superinfection Exclusion by Using Novel Fluorochrome Gene-Tagged Viral Genomes | Q27480348 | ||
Pre-existence and emergence of drug resistance in HIV-1 infection. | Q52264204 | ||
Superinfection and the evolution of parasite virulence. | Q52382956 | ||
The fate of competing beneficial mutations in an asexual population. | Q54262235 | ||
Antiretroviral dynamics determines HIV evolution and predicts therapy outcome | Q36374300 | ||
Mechanism-based pharmacodynamic modeling | Q36933670 | ||
Vacated niches, competitive release and the community ecology of pathogen eradication | Q37037427 | ||
Global control of hepatitis C: where challenge meets opportunity | Q37077112 | ||
Evasion of superinfection exclusion and elimination of primary viral RNA by an adapted strain of hepatitis C virus. | Q37336829 | ||
Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver | Q37684887 | ||
Genetic recombination of the hepatitis C virus: clinical implications | Q37828637 | ||
The role of mutational robustness in RNA virus evolution | Q38092577 | ||
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study | Q38375284 | ||
In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance | Q38868283 | ||
Modeling Viral Spread | Q38952060 | ||
Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells | Q40425026 | ||
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection | Q40908880 | ||
Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection | Q41722674 | ||
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin | Q42201573 | ||
Pre-existence and emergence of drug resistance in a generalized model of intra-host viral dynamics. | Q42277513 | ||
A comprehensive hepatitis C viral kinetic model explaining cure | Q42997057 | ||
Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics | Q42999813 | ||
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. | Q43039341 | ||
Influence of viral replication mechanisms on within-host evolutionary dynamics | Q46082049 | ||
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy | Q27860724 | ||
Coinfection and the evolution of parasite virulence | Q28290024 | ||
A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants | Q28473678 | ||
Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing | Q28482493 | ||
Evolutionary analysis of human immunodeficiency virus type 1 therapies based on conditionally replicating vectors | Q28484825 | ||
Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection | Q28545971 | ||
Antibody neutralization and escape by HIV-1 | Q29547345 | ||
Unifying the epidemiological and evolutionary dynamics of pathogens | Q29619092 | ||
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection | Q29619510 | ||
The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes | Q30004698 | ||
Influenza A virus uses intercellular connections to spread to neighboring cells | Q30616850 | ||
Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration | Q30685690 | ||
Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance | Q33631104 | ||
Low dynamic state of viral competition in a chronic avian hepadnavirus infection | Q33787127 | ||
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life | Q34035703 | ||
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants | Q34276394 | ||
Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model | Q34334375 | ||
Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate | Q34395271 | ||
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a | Q34451681 | ||
Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes | Q34504820 | ||
Rapid emergence of protease inhibitor resistance in hepatitis C virus | Q34551913 | ||
A perspective on modelling hepatitis C virus infection | Q34759489 | ||
Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver | Q34969032 | ||
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. | Q35012057 | ||
Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus | Q35164008 | ||
Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4 | Q35172385 | ||
The role of cells refractory to productive infection in acute hepatitis B viral dynamics | Q35691056 | ||
Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach | Q35745457 | ||
Origin and evolution of the unique hepatitis C virus circulating recombinant form 2k/1b | Q35826504 | ||
Characterization of Hepatitis C Virus Recombination in Cameroon by Use of Nonspecific Next-Generation Sequencing | Q36066888 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 30 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Hepatitis C virus | Q708693 |
superinfection | Q1563808 | ||
P304 | page(s) | E7139-E7148 | |
P577 | publication date | 2018-07-24 | |
P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
P1476 | title | Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence | |
P478 | volume | 115 |
Q63762397 | Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants |
Q64064863 | HCV transmission in high-risk communities in Bulgaria |
Q63740385 | Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs |
Q91867190 | Within-host infectious disease models accommodating cellular coinfection, with an application to influenza |
Search more.